Showing 2171-2180 of 9226 results for "".
- Daily SPF Use Lags Among Youth: Surveyhttps://practicaldermatology.com/news/daily-spf-use-lags-among-youth-in-multigenerational-skincare-survey/2488298/Interest in facial skincare is growing among children and adolescents, new findings suggest. Researchers evaluated a 3-product regimen consisting of a hydrating cream cleanser, hydrating moisturizer, and daily mineral SPF 40
- Upadacitinib Shows Sustained Responses in PsA After Prior TNF Inhibitor: Analysishttps://practicaldermatology.com/news/upadacitinib-shows-sustained-responses-in-psa-after-prior-tnf-inhibitor-analysis/2488287/A post hoc analysis of SELECT-PsA 2 found sustained responses with upadacitinib 15 mg once daily through 152 weeks among patients with psoriatic arthritis (PsA) previously exposed to 1 tumor necrosis factor inhibitor (TNFi). Published in RMD Open, the analysis included 195 patient
- Outpatient Dermatology Care Linked to Fewer HS Hospital Readmissions: Analysishttps://practicaldermatology.com/news/outpatient-dermatology-care-linked-to-fewer-hs-hospital-readmissions-analysis/2488266/Hidradenitis suppurativa (HS) carries a significant acute-care burden, but outpatient dermatology follow-up may be associated with fewer hospital readmissions, according to a study published in Archives of Dermatological Research
- GLP-1 Weight Loss Not Linked to Higher Body-Contouring Surgery Complication Rateshttps://practicaldermatology.com/news/glp-1-weight-loss-not-linked-to-higher-body-contouring-surgery-complication-rates/2488256/The method patients used to lose weight—including injectable glucagon-like peptide-1 (GLP-1) receptor agonist pharmacotherapy—was not associated with differences in postoperative complication rates after body-contouring surgery, according to a retrospective study p
- Brepocitinib Improves Cutaneous Dermatomyositis Outcomes Through 52 Weekshttps://practicaldermatology.com/news/brepocitinib-30-mg-improves-cutaneous-dermatomyositis-outcomes-through-52-weeks/2488228/Once-daily oral brepocitinib 30 mg improved skin disease activity, pruritus, and skin-related quality of life in adults with dermatomyositis as early as 4 weeks, according to results from an analysis of phase data from the 3 VALOR trial. The analysis included data from 241 adults with acti
- Skin Cancer Champions to Host Inaugural Patient Advocacy Summithttps://practicaldermatology.com/news/skin-cancer-champions-to-host-inaugural-patient-advocacy-summit/2488209/Skin Cancer Champions will convene its inaugural Patient Advocacy Summit on October 30, 2026, in Boston, Massachusetts, bringing patients and caregivers together with clinicians and industry representatives to discuss nonmelanoma skin cancer care, emerging therapies, and patient advocacy.
- Review Explores Energy-based Devices in Gender-affirming Carehttps://practicaldermatology.com/news/review-explores-energy-based-devices-in-gender-affirming-care/2488181/Laser and energy-based devices (EBDs) may address several dermatologic concerns relevant to transgender patients, from unwanted hair and acne to postoperative scars and body contouring, according to a recent review by Zarghami et al. Laser Applications Span Hair Removal, Acne, and Postsur
- Picosecond Laser Study Links Immediate Whitening to Skin Tissue Responsehttps://practicaldermatology.com/news/picosecond-laser-study-links-immediate-whitening-to-skin-tissue-response/2488179/A new in vivo study offers a closer look at what immediate whitening (IW) may represent at the tissue level following picosecond laser irradiation. Researchers publishing in Lasers in Surgery and Medicine, the study evaluated the relationship among IW, vacuole formation, and melan
- Cherry Angiomas Linked to NF1-Related Vascular Changes: Studyhttps://practicaldermatology.com/news/cherry-angiomas-linked-to-nf1-related-vascular-changes-study/2488158/Cherry angiomas may be a previously underrecognized vascular manifestation of neurofibromatosis type 1 (NF1), according to findings from a prospective comparative study in JAMA Dermatology. Investigators evaluated 259 participants (102 individuals with confirmed NF1 and 157 contro
- Phase 3 Study Shows Sustained Psoriasis Responses With SSGJ-608https://practicaldermatology.com/news/phase-3-study-shows-sustained-psoriasis-responses-with-ssgj-608/2488143/A phase 3 trial of the investigational interleukin (IL)-17A–targeting monoclonal antibody (SSGJ-608) showed high response rates through 52 weeks among adults with moderate-to-severe plaque psoriasis. Investigators for the double-blind, placebo-controlled trial included 458 adults in the sa